OncoZenge AB (SE:ONCOZ)
:ONCOZ
Top Page
OncoZenge AB
(ONCOZ)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr5.50
▼(-0.18% Downside)
Action:ReiteratedDate:03/01/26
The score is held down primarily by very weak financial performance (persistent losses, ongoing cash burn, and a 2025 balance sheet deterioration with negative equity and new debt). Technical indicators are moderately supportive with the price trading above key moving averages and a positive MACD, but valuation remains constrained because the company is loss-making (negative P/E).
Positive Factors
Niche oncology supportive-care focus
OncoZenge's clear strategic focus on oncology supportive care and a lead candidate targeting oral mucositis addresses a predictable, recurring complication of cancer therapy. That structural clinical need supports durable demand if regulatory and reimbursement milestones are reached.
Negative Factors
Weakened balance sheet, negative equity
Negative shareholders' equity and new debt materially increase solvency and refinancing risk. This structural deterioration reduces financial flexibility, raises cost of capital, and heightens the likelihood of dilutive or onerous financing decisions, impairing long-term funding of trials and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche oncology supportive-care focus
OncoZenge's clear strategic focus on oncology supportive care and a lead candidate targeting oral mucositis addresses a predictable, recurring complication of cancer therapy. That structural clinical need supports durable demand if regulatory and reimbursement milestones are reached.
Read all positive factors
OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr82.60M
Dividend YieldN/A
Average Volume (3M)35.93K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth20.55%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding14,048,068
10 Day Avg. Volume29,683
30 Day Avg. Volume35,930
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1
Revenue Forecast (FY)kr10.00M
OncoZenge AB Business Overview & Revenue Model
Company Description
OncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel ther...
How the Company Makes Money
OncoZenge’s primary expected way to make money is through commercialization of its lead drug candidate, BupiZenge, if it receives regulatory approval. In that scenario, revenue would typically come from product sales (either directly or via commer...
OncoZenge AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
20
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.66M | 1.00K | 3.00K | 0.00 | 0.00 |
| Gross Profit | -4.84M | 1.00K | 3.00K | 0.00 | 0.00 |
| EBITDA | -15.87M | -8.69M | 7.27M | 2.77M | -4.89M |
| Net Income | -15.94M | -8.69M | -15.90M | -46.65M | -3.89M |
Balance Sheet | |||||
| Total Assets | 15.34M | 11.43M | 20.34M | 36.89M | 85.23M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 3.86M | 12.63M | 29.14M | 51.22M |
| Total Debt | 7.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 15.92M | 1.48M | 1.70M | 2.92M | 4.90M |
| Stockholders Equity | -587.00K | 9.95M | 18.64M | 33.97M | 80.32M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -8.76M | -17.08M | -22.08M | -10.12M |
| Operating Cash Flow | -13.06M | -8.76M | -17.08M | -22.08M | -4.77M |
| Investing Cash Flow | 0.00 | 0.00 | 570.00K | 0.00 | -5.36M |
| Financing Cash Flow | 12.91M | 0.00 | 0.00 | 0.00 | 51.34M |
OncoZenge AB Technical Analysis
Positive
5.51
Price Trends
5.71
Positive
5.87
Positive
6.04
Negative
Market Momentum
-0.03
Negative
53.11
Neutral
40.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Positive. The current price of 5.51 is below the 20-day moving average (MA) of 5.72, below the 50-day MA of 5.71, and below the 200-day MA of 6.04, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 53.11 is Neutral, neither overbought nor oversold. The STOCH value of 40.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ONCOZ.
OncoZenge AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | kr311.27M | 1.48 | -264.12% | ― | -17.80% | -11.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr82.60M | -5.14 | -202.18% | ― | ― | 20.55% | |
43 Neutral | kr37.83M | -1.03 | -457.91% | ― | ― | -19.35% | |
41 Neutral | kr3.70M | -3.06 | -213.85% | ― | ― | ― | |
40 Underperform | kr20.90M | -1.19 | -88.65% | ― | 8.46% | 11.73% |
* Healthcare Sector Average
SE:ONCOZ
OncoZenge AB
5.88
0.48
8.89%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.08
-87.78%
SE:MODTX
Modus Therapeutics Holding AB
0.31
-0.18
-36.01%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
5.92
-12.32
-67.54%
SE:SPRINT
Sprint Bioscience AB
2.95
2.30
353.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.